Clinical Trial Update: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial comparing daily subcutaneous semaglutide to placebo and liraglutide in adults with type 2 diabetes. Completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2018-01-23